Program
zilucoplan
Also written as “Zilucoplan”, “zilucoplan (RA101495)” and “Zilucoplan (RA101495)”.
Its studies are mostly in Myasthenia Gravis · Hemoglobinuria, Paroxysmal · Muscular Diseases · COVID-19, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCB | 133 open or running | phase 3since Oct 2, 2019 | Jan 20, 2017 | Mar 23, 2027phase 1 · NCT06961747 |
| Amgen | 10 open or running | phase 3since Oct 14, 2020 | Oct 14, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 20, 2017First study: phase 2 study in Hemoglobinuria, ParoxysmalNew to UCBUCB · NCT03030183 · 3 enrolled · United States
- Mar 8, 2017Phase 2 study in Hemoglobinuria, ParoxysmalUCB · NCT03078582 · 26 enrolled · Australia, Canada, Denmark and more
- Jul 17, 2017Phase 2 study in Hemoglobinuria, ParoxysmalUCB · NCT03225287 · 19 enrolled · United States, Australia, Canada and more
- Oct 16, 2017Phase 2 study in Myasthenia GravisUCB · NCT03315130 · 45 enrolled · United States, Canada
- Jul 17, 2019Phase 2 study in Immune Mediated Necrotizing MyopathyUCB · NCT04025632 · 27 enrolled · United States, France, Netherlands and more
- Oct 2, 20192 phase 3 studies in Myasthenia GravisUCB · NCT04225871, NCT04115293
- Oct 14, 2020Amgen's first study: phase 3 study in COVID-19New to AmgenAmgen · NCT04590586 · 515 enrolled · United States, Argentina, Brazil and more
- Aug 22, 2022Phase 3 study in Myasthenia GravisUCB · NCT05514873 · 26 enrolled · United States
- Sep 20, 2023Phase 3 study in Myasthenia GravisUCB · NCT06055959 · 8 planned · United States, Italy, Poland and more
- May 23, 2024Phase 3 study in Myasthenia GravisUCB · NCT06435312 · 8 planned · Italy, Poland, South Korea and more
- Jun 18, 2024Phase 3 study in Myasthenia GravisUCB · NCT06471361 · 31 enrolled · United States, Poland, United Kingdom
- Jul 15, 2024Phase 1 study in Healthy VolunteersUCB · NCT06511076 · 14 enrolled · Netherlands
- Apr 29, 2025Phase 1 study in Healthy ParticipantsUCB · NCT06961747 · 15 planned · United States
- Nov 5, 2026Primary completion moved from 2026-11-16 to 2027-05-12Date moved laterphase 3 · +6 months · NCT06055959
Ahead
- Mar 23, 2027Primary completion: phase 1 study in Healthy ParticipantsUCB · NCT06961747
- May 12, 2027Primary completion: phase 3 study in Myasthenia GravisUCB · NCT06055959
- Oct 26, 2027Primary completion: phase 3 study in Myasthenia GravisUCB · NCT06435312
TargetBeta
“Complement C5 inhibitor”ChEMBL 37, by rule
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eculizumabrule | AstraZeneca | phase 4 | 38 |
| ravulizumabrule | AstraZeneca | phase 4 | 35 |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 14 |
| vilobelimabrule | inflarx-gmbh | phase 3 | 13 |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 10 |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| ABBV-6628 | AbbVie | phase 2 | 1 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06961747Healthy Participants · United States | 1 | Recruiting | UCB | Mar 23, 2027 | 15 |
| NCT06511076Healthy Volunteers · Netherlands | 1 | Completed | UCB | Nov 26, 2024 | 14 |
| NCT06471361Myasthenia Gravis · United States, Poland, United Kingdom | 3 | Completed | UCB | Jan 28, 2025 | 31 |
| NCT06435312Myasthenia Gravis · Italy, Poland, South Korea and more | 3 | By invitation | UCB | Oct 26, 2027 | 8 |
| NCT06055959Myasthenia Gravis · United States, Italy, Poland and more | 3 | Recruiting | UCB | May 12, 2027 | 8 |
| NCT05514873Myasthenia Gravis · United States | 3 | Completed | UCB | Mar 13, 2024 | 26 |
| NCT04590586COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | Amgen | Aug 3, 2021 | 515 |
| NCT04225871Myasthenia Gravis · United States, Canada, France and more | 3 | Completed | UCB | Jul 31, 2026 | 200 |
| NCT04115293Myasthenia Gravis · United States, Canada, France and more | 3 | Completed | UCB | Dec 30, 2021 | 174 |
| NCT04025632Immune Mediated Necrotizing Myopathy · United States, France, Netherlands and more | 2 | Terminated | UCB | Mar 4, 2021 | 27 |
| NCT03315130Myasthenia Gravis · United States, Canada | 2 | Completed | UCB | Dec 10, 2018 | 45 |
| NCT03225287Hemoglobinuria, Paroxysmal · United States, Australia, Canada and more | 2 | Terminated | UCB | Sep 7, 2021 | 19 |
| NCT03078582Hemoglobinuria, Paroxysmal · Australia, Canada, Denmark and more | 2 | Completed | UCB | Mar 28, 2018 | 26 |
| NCT03030183Hemoglobinuria, Paroxysmal · United States | 2 | Completed | UCB | Mar 28, 2018 | 3 |
How it is read
Names in the registry
- “Zilucoplan”, 6 entries
- “zilucoplan (RA101495)”, 4 entries
- “Zilucoplan (RA101495)”, 3 entries
- “zilucoplan”, 1 entry
Conditions, from the studies’ own filings
- Myasthenia Gravis, 7 studies
- Hemoglobinuria, Paroxysmal, 3 studies
- Muscular Diseases, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.